Besides germline and somatic mutations, epigenetic modifications like promoter hypermethylation of BRCA1 can also lead to downregulation of gene expression [3, 4] and thus silencing of the BRCA1. Methylation of CpG islands in the BRCA1 promoter of primary high-grade ovarian carcinomas has been described ranging from 11-89% [1, 5-8]. The gene discussed is BRCA1; the disease is ovarian carcinoma.